Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRT13722 |
| Synonyms | |
| Therapy Description |
PRT13722 is a selective KAT6A degrader, which potentially inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 5793). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRT13722 | PRT 13722|PRT-13722 | PRT13722 is a selective KAT6A degrader, which potentially inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 5793). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07905001 | Phase I | PRT13722 Fulvestrant + PRT13722 Abemaciclib + Fulvestrant + PRT13722 Imlunestrant + PRT13722 | A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer | Recruiting | USA | 0 |